Uroguanylin: A new actor in the energy balance movie

C. Folgueira, S. Barja-Fernandez, P. Gonzalez-Saenz, V. Pena-Leon, C. Castelao, M. Ruiz-Piñon, F. F. Casanueva, R. Nogueiras, L. M. Seoane*

*Autor corresponent d’aquest treball

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

12 Cites (Scopus)

Resum

Uroguanylin (UGN) is a potential target in the fight against obesity. The mature protein is released after enzymatic cleavage from its natural precursor, proUGN. UGN is mostly produced in the gut, and its production is regulated by nutritional status. However, UGN is also produced in other tissues such as the kidneys. In the past, UGN has been widely studied as a natriuretic peptide owing to its involvement in several different pathologies such as heart failure, cancer and gastrointestinal diseases. However, recent studies have suggested that UGN also acts as a regulator of body weight homeostasis because it modulates both food intake and energy expenditure. This ultimately results in a decrease in body weight. This action is mediated by the sympathetic nervous system. Future studies should be directed at the potential effects of UGN agonists in regulating body weight in human obesity.

Idioma originalAnglès
Pàgines (de-a)R31-R38
Nombre de pàgines8
RevistaJournal of Molecular Endocrinology
Volum60
Número2
DOIs
Estat de la publicacióPublicada - de febr. 2018
Publicat externament

Fingerprint

Navegar pels temes de recerca de 'Uroguanylin: A new actor in the energy balance movie'. Junts formen un fingerprint únic.

Com citar-ho